Drug Database
BA

Bacillus Calmette-Guerin vaccine

✓ Approved

Verity Pharmaceuticals Inc · 细胞治疗 · 细胞治疗

什么是 Bacillus Calmette-Guerin vaccine?

Bacillus Calmette-Guerin vaccine 是一种细胞治疗,由Verity Pharmaceuticals Inc研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravesical Injection。

药物档案

公司Verity Pharmaceuticals Inc
药物类别细胞治疗, 疫苗
给药途径Injectable (Others), Intravesical Injection
状态Approved

治疗适应症

Bacillus Calmette-Guerin vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Bladder cancer✓ Approved

相关研究文献

PubMedClinical cancer research : an official journal of the American Association for Cancer Research2026-11-17

Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Phase I Trial.

Osorio Juan C JC, Blanchard Lucas L, Yao Ning N, Alam Syed M SM et al.

CD40 agonists activate dendritic cells (DCs) and promote T-cell antitumor immunity, but clinical development has been limited by systemic toxicity and incomplete understanding of determinants of response. In this phase I study (NCT05126472), we evaluated the safety, preliminary clinical activity, and spatial immune correlates of response to intravesical Fc-optimized CD40 agonist 2141-V11 in 25 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Patients received weekly intravesical instillations for 3 weeks, with retreatment at weeks 13 and 25 based on disease status. Primary objectives were safety, tolerability, and determination of the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Secondary endpoints included pharmacokinetics and preliminary clinical activity. Exploratory endpoints including multiplex spatial profiling on tumor specimens to define correlates of response. Intravesical 2141-V11 was well tolerated, and the MTD was not reached. The RP2D was established at 70 mg. Preliminary clinical activity was observed in 40% of patients, with a median response duration of 20 months. Clinical response was associated with distinct organization of tertiary lymphoid structures, characterized by the presence of DC-CXCL13+ CD4+ and CD8+ T cell triads. Following treatment, responders exhibited decreased proximity between DCs and regulatory T cells (Tregs), whereas non-responders exhibited increased DC-Treg proximity. Intravesical 2141-V11 demonstrated a favorable safety profile and preliminary antitumor activity. Spatial profiling revealed immune-cell organizations associated with clinical response, identifying candidate biomarkers and potential strategies for therapeutic combinations. These findings support further clinical evaluation of intravesical 2141-V11 in phase II studies.

PMID 43043010
阅读全文 →
PubMedMicrobial cell factories2026-11-17

Construction and immunogenicity evaluation of recombinant Bacillus subtilis expressing VP8 protein of porcine rotavirus.

Wang Zhikui Z, Yan Xinping X, Wang Xu X, Yue Xiaoxue X et al.

Porcine rotavirus (PoRV), an enteric infectious virus, is a major cause of neonatal diarrhea in piglets, resulting in significant economic losses to the global swine industry. In this study, the cholera toxin B subunit (CTB) was utilized as a molecular adjuvant to construct recombinant Bacillus subtilis (B. subtilis) strains expressing VP8 proteins and CTB-VP8 fusion proteins derived from the PoRV genotypes P[7], P[13], and P[23]. The recombinant strains expressing PoRV proteins from different genotypes were combined and orally administered to mice, and their immunogenicity and probiotic functions were evaluated. The results demonstrated that the recombinant B. subtilis significantly increased serum-specific IgG and fecal-specific sIgA antibodies levels (P < 0.001), indicating that the recombinant strains induced both humoral and mucosal antibody responses in mice. Notably, the CTB-fused strains elicited higher titers of IgG and sIgA. Furthermore, the recombinant strains significantly elevated the expression levels of cytokines, including IFN-γ, IL-2, and IL-4, in both serum and intestinal mucosa (P < 0.01), suggesting a Th1/Th2-biased immune response at the cytokine level. In addition, administration of recombinant B. subtilis increased villus height and the villus height-to-crypt depth ratio while reducing crypt depth, showing a tendency to improve intestinal morphology. This study addresses the limitations associated with insufficient mucosal immune activation by conventional injectable approaches and the absence of cross-protection among different genotypes of PoRV, thereby providing a theoretical foundation for the development of an oral trivalent live-vector vaccine.

PMID 43040377
阅读全文 →
PubMedBMC public health2026-11-17

Post-introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023.

Amponsa-Achiano Kwame K, Shen Angela K AK, Baiden Laryea Eunice E, Carlton Julie Garon JG et al.

On March 2nd, 2021, Ghana, the first country to receive vaccines from the COVAX facility, began its COVID-19 vaccination using a complex multi-phased approach, to reach target populations. We evaluated the vaccine deployment to document best practices challenges and lessons for future new vaccine introductions and public health emergency readiness. We conducted a mixed methods post-introduction evaluation, purposively sampling 36 facilities from 12 districts in six regions. Adapting the World Health Organization's COVID-19 Post-Introduction Evaluation tool, we conducted a cross-sectional survey using a structured questionnaire, reviewed programme records, observed practices, and interviewed purposively selected health workers, immunization managers and partners who supported vaccine deployment. We performed summary descriptive statistics on quantitative data, thematic analysis on qualitative data, and triangulated the results. As of March 2023, more than 70% of the target population (15 years and older) had received at least one dose, while more than 50% had completed the primary series. Vaccine deployment was built on the existing immunisation programme and functional coordinating bodies. Cold chain capacity was revamped with ultra-low-temperature freezers, while 33.3% of surveyed districts adjusted waste disposal systems to accommodate COVID-19 vaccine introduction. Door-to-door delivery and demand generation through varied risk communication and community engagement strategies improved vaccine access. Electronic data platforms were established, surge capacity improved, and healthcare and community workers were trained. Initial unpredictable vaccine supplies limited vaccination efforts. Changing vaccine information affected health workers' ability to engage communities with up-to-date guidance. While vaccine safety monitoring systems were in place, reporting knowledge varied among health workers, and 36% of surveyed facilities had ever documented and reported COVID-19 vaccine-related adverse events following immunisation. Challenges with electronic data systems limited timely access to and use of granular service-delivery data for decision-making. Ghana leveraged existing immunisation and emergency-response systems to make substantial progress in COVID-19 vaccine deployment. Coordination, cold chain expansion, flexible service delivery, demand generation and workforce mobilisation supported implementation. Irregular vaccine supply, data system challenges, variable adverse event reporting, waste management pressure and misinformation challenged deployment. These findings provide lessons for adult immunisation, life-course vaccination and future public health emergency readiness.

PMID 43040294
阅读全文 →
PubMedJournal of economic entomology2026-11-17

Profiling cultivable bacteria in Forcipomyia spp. (Diptera: Ceratopogonidae), feeding on the silkworm Antheraea mylitta (Lepidoptera: Saturniidae): insights into possible transmission routes.

Maitra Mazumdar Shuddhasattwa S, Banerjee Nabanita N, Sarkar Ankita A, Saha Arijit A et al.

The co-occurrence of Antheraea mylitta Drury larvae (commonly known as tasar silkworm) and hemolymph-feeding Forcipomyia spp. (commonly known as biting midges) in the same habitat increases the likelihood of interaction and pathogen transmission. This study investigated bacterial species shared between Forcipomyia fuliginosa Meigen, Forcipomyia esakiana Tokunaga, and A. mylitta, with emphasis on potential pathogens affecting silk productivity, a sector valued at USD 220.58 million as of 2022 to 2023. As tasar rearing occurs outdoors, larvae are at risk of a plethora of biotic stressors, from prey and predators to pathogens. Cultivable bacteria were isolated from the gut and salivary glands of adult midges following their feeding on 5th instar silkworm larvae. The bacterial isolates obtained from these 2 tissues were then compared with those recovered from healthy and diseased 5th instar larvae to assess similarities and differences in bacterial composition. Bacterial identification was done using DNA barcoding, colony morphology, and biochemical characterization. The isolates belonged to Firmicutes (Bacillaceae), mainly Bacillus and Lysinibacillus. Common strains included Bacillus cereus FFG1, Bacillus thuringiensis IL4, Lysinibacillus fusiformis FFG3, and Lysinibacillus boronitolerans FFG2, the latter being the most prevalent. Bacillus subtilis FFS5 was found only in the salivary gland of F. fuliginosa, while all gut bacteria were also present in salivary glands. Transmission studies detected B. cereus and B. thuringiensis in adult A. mylitta but not in eggs or early larvae, suggesting unlikely trans-ovarian or trans-stadial transmission and a possible vector-mediated role of Forcipomyia spp. This study provides the first baseline report of their cultivable bacterial communities.

PMID 43042937
阅读全文 →
PubMedACI open2026-11-17

Enhancing Human Papillomavirus Vaccine Communication with Mobile Health: Usability Insights from Caregivers and Health Care Providers.

Reisher Elizabeth E, Anyanwu Evangel E, Figliomeni Jonathan J, Honcoop Adrien A et al.

Despite the effectiveness of the human papillomavirus (HPV) vaccine in preventing cancer, uptake remains suboptimal, especially among rural and underserved populations. Digital communication tools such as mobile health (mHealth) applications have the potential to improve access to accurate vaccine information and support shared decision-making. This study aimed to assess the usability, acceptability, and perceived usefulness of a newly developed mHealth app for HPV vaccine communication in comparison to the Centers for Disease Control and Prevention's (CDC) HPV vaccine Web site. Using a mixed-methods design and guided by the Health Belief Model and the mHealth Agile Development and Evaluation Lifecycle, caregivers, and health care providers were randomized to explore both the CDC Web site and the mHealth app in alternating order. Participants were asked to complete a session answering HPV vaccine questions with each tool and completed the mHealth App Usability Questionnaire, Propensity to Trust, and NASA Task Load Index (NASA-TLX) after each session. Qualitative questions were asked after each session to capture additional feedback on items such as navigation and readability. Transcripts were analyzed using inductive thematic analysis. Quantitative results showed no difference between the tools in terms of being easy to use, requiring similar amounts of effort, and trust in the tool. Qualitative themes revealed that participants appreciated the app's streamlined navigation, tailored content, and readability. In contrast, the CDC Web site was seen as credible but often difficult to navigate, especially when searching for nuanced or specific vaccine information. Tailored mHealth tools developed with user-centered design principles may better meet the informational and usability needs of caregivers and health care providers compared with existing web-based resources. These findings support further development and integration of mHealth tools into vaccine communication strategies to enhance HPV vaccine communication.

PMID 43042227
阅读全文 →
PubMedInfection and immunity2026-11-17

Co-administration of DTaP with COVID-19 mRNA vaccine in mice alters immune responses and induces increased protection from Bordetella pertussis challenge.

Rader Nathaniel N, Boehm Dylan T DT, Bitzer Graham J GJ, Chapman Joshua J et al.

During the COVID-19 pandemic, children received COVID-19 mRNA vaccines alongside other regularly scheduled immunizations, such as the acellular Bordetella pertussis vaccine DTaP. It is known that mRNA vaccines are pro-inflammatory in nature, leading to protective immunity against SARS-CoV-2 infection. The goal of this study was to investigate the potential adjuvanticity of co-administration of a COVID-19 mRNA vaccine alongside DTaP. Mice were immunized with DTaP alone or with a co-administration of DTaP plus COVID-19 mRNA vaccine. To understand the impact of co-administration, we evaluated protection against B. pertussis aerosol challenge in mice and potential correlates of protection, including cytokine responses to vaccination, antibody responses, and single-cell transcriptomic analysis of the draining lymph node. Three decreasing doses of each vaccine were used to simulate waning immunity. Overall, compared to mice immunized with DTaP, co-administration of DTaP + COVID-19 mRNA vaccines elicited higher pro-inflammatory cytokine responses, higher IgG2b antibody responses, and mice were afforded increased protection against aerosol challenge of B. pertussis. Single-cell transcriptomics studies on the lymph node of vaccinated mice at 1 day post-boost further characterized how co-administration of COVID-19 mRNA vaccine alongside DTaP vaccine shapes immunity. Single-cell transcriptomics revealed that co-administration of DTaP and COVID-19 mRNA vaccine generated populations of B and T cells with upregulated expression of interferon-stimulated genes, which were absent when vaccinating with DTaP alone. Altogether, these data suggest that administering DTaP alongside COVID-19 mRNA vaccine alters immune responses and provides increased protection from an aerosol challenge of B. pertussis compared to DTaP alone in mice.

PMID 43043313
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Bacillus Calmette-Guerin vaccine